Eli Lilly's tirzepatide shows a 94% reduction in diabetes risk and significant weight loss in adults with pre-diabetes and obesity, according to a three-year study.

Discover the unexpected U.S. state leading the surge in GLP-1 weight loss drug usage, driven by celebrity endorsements and healthcare innovations, with significant economic implications.

New analysis reveals 85% of individuals stop using GLP-1 drugs for weight loss after two years. Learn about adherence trends and the role of fitness centers like Equinox and MIORA by Life Time in obesity management.

A recent ukactive survey reveals that 85% of UK adults prefer the Government to invest in long-term obesity prevention rather than weight-loss drugs. Discover public opinions on health priorities, mental health support, and the role of gyms in healthcare.

WHO warns about the spread of counterfeit Ozempic in Europe and the Americas. Learn how fake diabetes medication poses health risks and the measures to ensure drug authenticity and safety.

24 Hour Fitness introduces new group classes focused on longevity and recovery, designed to enhance physical resilience, prevent injuries, and improve overall fitness and quality of life.

New study by BCBSA reveals 58% of patients discontinue GLP-1 weight loss drugs before seeing benefits. Fitness industry partnerships could help improve adherence and outcomes.

Discover Ro's new GLP-1 Supply Tracker, providing real-time insights into GLP-1 drug shortages. Learn how this tool helps manage medication availability as demand for weight loss drugs rises.

Discover how MyFitnessPal is revolutionizing weight loss support with new tools for GLP-1 medication users, enhancing tracking and nutrition management to promote sustainable health improvements. Explore our comprehensive approach to integrating fitness with medication management.

The fitness industry is currently navigating new terrain with the emergence of GLP-1 and weight-loss drugs, sparking a debate on integrating these medical advances into fitness programs. This comes at a time when media mogul Oprah Winfrey revisited television with a special that highlighted the complexities of obesity as a disease and the potential life-altering impact of weight-loss medications such as Wegovy and Zepbound.

Explore the FDA's landmark approval of Wegovy, the first weight-loss medication also certified to reduce cardiovascular risks in obese or overweight adults. Learn how this breakthrough could revolutionize treatments and improve public health.

Explore how the fitness industry adapts to the surge in weight-loss drugs with insights from Bloomberg's latest survey on food companies' strategic shifts towards healthier options. Discover the future of wellness.

Explore the intricacies of the GLP-1 supplement trend with a focus on consumer health, informed choices, and the importance of professional guidance in the pursuit of wellness.

Learn about the rising cases of semaglutide overdose reported by American Poison Centers and the growing use of weight loss medications like Ozempic® and Wegovy®. Understand the risks associated with these drugs, initially developed for type 2 diabetes but now popular for weight loss.